Evidence map›Paper›PMID 33798923›Full record

ArticleAtherosclerosis2021

Inducible phospholipid transfer protein deficiency ameliorates atherosclerosis.

Ke Zhang, Jiao Zheng, Yunqin Chen, Jibin Dong, Zhiqiang Li, Yeun-Po Chiang, Mulin He, Qingxia Huang, Huiru Tang, Xian-Cheng Jiang

Open access · greenAbstract read
In one paragraph

Article in Atherosclerosis, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 12 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Ke ZhangDepartment of Cell Biology, State University of New York Downstate Health Sciences University, Brooklyn, New York, USA; Department of Emergency, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China.
Jiao ZhengDepartment of Cell Biology, State University of New York Downstate Health Sciences University, Brooklyn, New York, USA; Beijing University of Chinese Medicine, Beijing, China.
Yunqin ChenFudan University, Shanghai, China.
Jibin DongFudan University, Shanghai, China.
Zhiqiang LiDepartment of Cell Biology, State University of New York Downstate Health Sciences University, Brooklyn, New York, USA; Molecular and Cellular Cardiology Program, VA New York Harbor Healthcare System, Brooklyn, New York, USA.
Yeun-Po ChiangDepartment of Cell Biology, State University of New York Downstate Health Sciences University, Brooklyn, New York, USA.
Mulin HeDepartment of Cell Biology, State University of New York Downstate Health Sciences University, Brooklyn, New York, USA.
Qingxia HuangFudan University, Shanghai, China.
Huiru TangFudan University, Shanghai, China.
Xian-Cheng JiangDepartment of Cell Biology, State University of New York Downstate Health Sciences University, Brooklyn, New York, USA; Molecular and Cellular Cardiology Program, VA New York Harbor Healthcare System, Brooklyn, New York, USA. Electronic address: XJiang@downstate.edu.
State University of New York · USFudan University · CN

Funding

Effect of sphingomyelin biosynthesis on atherosclerosisR01HL149730 · NHLBI · SUNY DOWNSTATE MEDICAL CENTER · PI JIANG, XIAN-CHENG · 2020 to 2023
$1.9M
Effects of PC remodeling on macrophages and adipocytes: its relevance to atherosclerosisR01HL139582 · NHLBI · SUNY DOWNSTATE MEDICAL CENTER · PI JIANG, XIAN-CHENG · 2018 to 2021
$1.6M
The Effect of SPT Deficiency on AtherosclerosisI01BX000900 · VA · VA NEW YORK HARBOR HLTHCARE/SYS/BROOKLYN · PI JIANG, XIAN-CHENG · 2012 to 2025
–
BLRD VA I01 BX000900NHLBI NIH HHS R01 HL139582NHLBI NIH HHS R01 HL149730
6 · The paper itself

Abstract

BACKGROUND AND

aimsAtherosclerosis progression and regression studies are related to its prevention and treatment. Although we have gained extensive knowledge on germline phospholipid transfer protein (PLTP) deficiency, the effect of inducible PLTP deficiency in atherosclerosis remains unexplored.

methodsWe generated inducible PLTP (iPLTP)-knockout (KO) mice and measured their plasma lipid levels after feeding a normal chow or a Western-type diet. Adenovirus associated virus-proprotein convertase subtilisin/kexin type 9 (AAV-PCSK9) was used to induce hypercholesterolemia in the mice. Collars were placed around the common carotid arteries, and atherosclerosis progression and regression in the carotid arteries and aortic roots were evaluated.

resultsOn a normal chow diet, iPLTP-KO mice exhibited decreased cholesterol, phospholipid, apoA-I, and apoB levels compared with control mice. Furthermore, the overall amount of high-density lipoprotein (HDL) particles was reduced in these mice, but this effect was more profound for larger HDL particles. On a Western-type diet, iPLTP-KO mice again exhibited reduced levels of all tested lipids, even though the basal lipid levels were increased. Additionally, these mice displayed significantly reduced atherosclerotic plaque sizes with increased plaque stability. Importantly, inducible PLTP deficiency significantly ameliorated atherosclerosis by reducing the size of established plaques and the number of macrophages in the plaques without causing lipid accumulation in the liver.

conclusionsInduced PLTP deficiency in adult mice reduces plasma total cholesterol and triglycerides, prevents atherosclerosis progression, and promotes atherosclerosis regression. Thus, PLTP inhibition is a promising therapeutic approach for atherosclerosis.

Indexed as

AtherosclerosisPhospholipid Transfer ProteinsAnimalsMiceMice, Inbred C57BLMice, Knockoutphospholipid transfer protein, mousePhospholipid Transfer ProteinsAtherosclerosis progression and regressionInducible PLTP gene knockout miceLipoprotein metabolismStability of atherosclerotic plaque

Identifiers

PMID33798923
PMCPMC8096707
OpenAlexW3136444981

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.